Trial Profile
Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Cardiovascular disorders; Dilated cardiomyopathy; Heart failure
- Focus Adverse reactions
- Acronyms IMPACT-DCM
- Sponsors Vericel Corporation
- 03 Jan 2013 New trial record